Skip to main content

Advertisement

Table 1 Overall mortality and mortality rate ratios at diagnosis/index date for soft tissue sarcoma patients (N = 1246) and the general comparison cohort (N = 6230)

From: Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study

   STS patient mortality % (95% CI) General comparison mortality % (95% CI) Crude MRR (95% CI) Adjusted MRR (95% CI)*
0 to 5 years
Gender Female 40.2 (36.4-44.3) 10.7 (9.7-11.9) 4.8 (4.1-5.7) 4.7 (3.9-5.6)
  Male 41.6 (37.9-45.5) 13.5 (12.4-14.7) 3.9 (3.4-4.6) 4.2 (3.6-4.9)
Age (years) 0-39 27.2 (22.5-32.7) 0.3 (0.1-0.7) 116.7 (42.7-318.6) 110.8 (40.5-303.0)
  40-59 24.4 (20.3-29.2) 2.4 (1.8-3.3) 11.5 (8.0-16.4) 11.0 (7.6-15.8)
  60-79 53.9 (49.5-58.5) 16.5 (15.1-18.1) 4.7 (4.0-5.5) 4.4 (3.7-5.1)
  ≥ 80 72.2 (64.3-79.6) 51.2 (47.4-55.1) 1.9 (1.5-2.4) 1.9 (1.5-2.4)
Comorbidity None 34.9 (31.9-38.0) 7.0 (6.3-7.8) 6.2 (5.4-7.2) 6.6 (5.7-7.7)
  Low 52.3 (43.3-62.0) 24.3 (21.2-27.8) 2.9 (2.1-3.9) 3.0 (2.2-4.1)
  Moderate 60.6 (51.5-69.7) 34.2 (29.7-39.2) 2.5 (1.9-3.4) 2.8 (2.1-3.8)
  High 68.7 (58.8-78.2) 48.9 (43.0-55.3) 1.8 (1.3-2.4) 2.0 (1.4-2.7)
Total   41.0 (38.3-43.7) 12.2 (11.4-13.0) 4.3 (3.8-4.8) 4.4 (3.9-4.9)
5 to 10 years
Gender Female 16.0 (12.3-20.6) 11.7 (10.4-13.1) 1.4 (1.1-2.0) 1.8 (1.3-2.5)
  Male 19.2 (15.4-23.9) 15.2 (13.8-16.7) 1.3 (1.0-1.7) 1.5 (1.2-2.0)
Age (years) 0-39 8.1 (5.1-13.0) 0.8 (0.4-1.4) 11.1 (5.1-24.6) 11.1 (5.0-24.6)
  40-59 12.4 (8.8-17.3) 4.4 (3.5-5.6) 3.1 (2.0-4.8) 2.9 (1.8-4.4)
  60-79 28.4 (22.3-35.8) 24.3 (22.2-26.5) 1.2 (0.9-1.6) 1.2 (0.9-1.6)
  ≥ 80 60.0 (42.8-77.7) 64.0 (57.9-70.0) 1.0 (0.6-1.7) 1.1 (0.7-1.7)
Comorbidity None 13.7 (11.1-16.9) 11.1 (10.1-12.2) 1.4 (1.1-1.8) 1.5 (1.2-2.0)
  Low 41.3 (26.5-60.4) 23.0 (18.8-27.9) 1.3 (0.8-2.3) 1.6 (0.9-2.8)
  Moderate 44.9 (30.6-62.3) 23.9 (19.9-28.6) 1.9 (1.1-3.3) 2.8 (1.6-4.9)
  High 32.9 (17.8-55.7) 20.1 (15.6-25.6) 0.7 (0.3-1.5) 0.9 (0.4-2.0)
Total   17.7 (14.9-20.9) 13.5 (12.5-14.5) 1.4 (1.1-1.7) 1.6 (1.3-2.0)
  1. NOTES: Abbreviations: STS soft tissue sarcoma, MRR mortality rate ratio, CI confidence interval. *Adjusted for age, gender, and level of comorbidity.